Spike Glycoprotein, Coronavirus
"Spike Glycoprotein, Coronavirus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class I viral fusion protein that forms the characteristic spikes, or peplomers, found on the viral surface that mediate virus attachment, fusion, and entry into the host cell. During virus maturation, it is cleaved into two subunits: S1, which binds to receptors in the host cell, and S2, which mediates membrane fusion.
| Descriptor ID |
D064370
|
| MeSH Number(s) |
D12.776.543.512.500.665 D12.776.964.970.880.910.665
|
| Concept/Terms |
Spike Glycoprotein, Coronavirus- Spike Glycoprotein, Coronavirus
- Coronavirus Spike Glycoprotein
- Spike Protein, Coronavirus
- Coronavirus Spike Protein
- Glycoprotein S, Coronavirus
- Spike Glycoproteins, Coronavirus
|
Below are MeSH descriptors whose meaning is more general than "Spike Glycoprotein, Coronavirus".
Below are MeSH descriptors whose meaning is more specific than "Spike Glycoprotein, Coronavirus".
This graph shows the total number of publications written about "Spike Glycoprotein, Coronavirus" by people in this website by year, and whether "Spike Glycoprotein, Coronavirus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 1 | 3 | 4 |
| 2021 | 4 | 13 | 17 |
| 2022 | 1 | 11 | 12 |
| 2023 | 0 | 1 | 1 |
| 2024 | 2 | 3 | 5 |
| 2025 | 2 | 5 | 7 |
| 2026 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Spike Glycoprotein, Coronavirus" by people in Profiles.
-
Cellular immune responses 12 months after fractional or standard dose BNT162b2 booster vaccination in Mongolian adults. Front Immunol. 2026; 17:1779435.
-
Age-related differences in mRNA vaccine immunogenicity and adjuvancy. Immunol Cell Biol. 2026 Apr; 104(4):400-414.
-
The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances. Vaccine. 2026 Mar 19; 76:128348.
-
Elevated SARS-CoV-2 IgG4 in plasma and mucosa following repeated mRNA boosters impact antibody functions to Omicron and sarbecoviruses. EBioMedicine. 2026 Jan; 123:106087.
-
Common cold embecovirus imprinting primes broadly neutralizing antibody responses to SARS-CoV-2 S2. J Exp Med. 2025 Dec 01; 222(12).
-
HLA-B*15:01-positive severe COVID-19 patients lack CD8+ T cell pools with highly expanded public clonotypes. Proc Natl Acad Sci U S A. 2025 Sep 09; 122(36):e2503145122.
-
Genetic markers of enhanced functional antibody responses to COVID-19 vaccination. Vaccine. 2025 Aug 13; 61:127379.
-
SARS-CoV-2 ORF3a drives dynamic dense body formation for optimal viral infectivity. Nat Commun. 2025 May 12; 16(1):4393.
-
Using SARS-CoV-2 red cell kodecytes to assess vaccine-induced immune response to the conserved 1147-58 region of the spike protein in Indian blood donors: exploring the potential role of blood transfusion services in population surveillance. Transfus Clin Biol. 2025 Aug; 32(3):286-291.
-
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost. Nat Commun. 2025 Jan 17; 16(1):759.